Bioanalytical Systems Inc. narrowed its losses in the second fiscal quarter despite a 2 percent drop in revenue, the West
Lafayette-based contract research firm said late last week.
West Lafayette-based Bioanalytical Systems Inc. has promoted Anthony S. Chilton to CEO following the retirement of top executive
Richard M. Shepperd earlier this year.
Bloomington led the nation as the No. 1 small city in medical devices and equipment.
There has been a noticeable uptick in the level of health care real estate development activity this year.
The Indianapolis unit of Dow Chemical sees quarterly profit rise 6 percent, to $384 million, despite an 8-percent dip in revenue.
The parent company reports strongest quarterly results in more than a year.
Purdue University’s decision to close the Chao Center in West Lafayette is a setback for Indiana’s effort to grow
a vibrant contract drug manufacturing sector. But it’s just the latest in a series of unexpected changes—not all for
the worse—since Indianapolis-based BioCrossroads launched a contract drug manufacturing initiative in late 2007.
A federal judge has rejected Guidant Corp.'s guilty plea to charges it hid defects in heart defibrillators, after some
doctors and patients complained about the $296 million deal.
The Purdue Research Foundation says the Chao Center for Industrial Pharmacy and Contract Manufacturing was unable to become
self-sustaining in part because of the recession.
The upstart developer of a device to help doctors choose the right-sized stent to prop open clog-prone arteries has brought
aboard former Guidant Corp. executives, including Bill McConnell. Their regulatory and marketing expertise could help FlowCo Inc. bring its artery-measurement
product to market as soon as 2011.
Eli Lilly and Co. will repurchase rights to develop and market antidepressant Cymbalta outside the U.S. and Japan from European
partner Boehringer Ingelheim for an initial payment of $400 million.
Indianapolis-based Eli Lilly and Co. sued rival drugmaker Hospira Inc. to prevent it from selling a generic version of the
cancer drug Gemzar before a patent on the medicine expires in 2013.
Monday’s decision throws out a $65.2 million patent-infringement verdict won by Ariad for royalties on Lilly’s osteoporosis
drug Evista and sepsis medicine Xigris.
Eli Lilly & Co., the maker of the impotence pill Cialis, bought exclusive rights from Australia’s Acrux Ltd. to
an underarm testosterone lotion called Axiron for men with limited sex drive due to low levels of the hormone.
Regulators won’t require more time-consuming tests of the drug, but want Eli Lilly and Co. and its partners to clarify labeling,
manufacturing
processes.
The acquisition will benefit Elanco, Lilly’s animal health division in Greenfield, which has become increasingly important
to Lilly as it braces for patent-protection losses.
Agricultural biotech firm hired a site-selection consultant and considered other cities around the world for its $340 million
expansion.
The investment will greatly expand the company’s research and development capacity and is a major win for the Indiana
life sciences industry. Dow AgroSciences expects most of the positions to pay between $65,000 and $95,000 annually.
The former Guidant Corp. CEO and long-time Eli Lilly exec said he and his family will be returning to Indianapolis.
Local Dow Chemical subsidiary expects to launch five new biotech products by 2012.
Greenfield Labs operation expects to add 17 Eli Lilly and Co. workers after taking over staff of 264 in 2008 acquisition.
